Researchers led by the Tokyo Medical and Dental University (TMDU) have found that antibody fragments encapsulated in nanomicelles can cross the blood-brain barrier and reduce levels of toxic A?.Intracerebral seeds in Alzheimer’s disease model mice
Sometimes the best things in life happen by chance. Now, Japanese researchers have discovered a way to ensure that new drugs are delivered to the right place in the body and at the right time in the progression of the disease for the best possible effect.
In a study recently published in the Journal of Nanobiotechnology, researchers led by Tokyo Medical and Dental University (TMDU) found that a novel delivery system delivers treatment where it is most needed in a mouse model of Alzheimer’s disease (AD). made it clear.
AD is a common neurodegenerative disease that causes dementia. It is characterized by the accumulation of amyloid-β protein. (A?) is in the brain and there are several different toxic forms of A?. It has been confirmed to impair brain function, especially A?. Oligomers (A?Os).
“Have multiple clinical trials attempted the use of anti-A antibodies? We have developed antibodies to treat AD, but the results have been unsatisfactory.” First, the blood-brain barrier (BBB) prevents most full-length antibodies from entering the brain.”
To address this challenge, researchers previously developed glycosylated (sugar-linked) polymeric nanomicelles (PMs). This process was mediated by glucose transporter-1 and induced by elevated blood glucose levels after mice experienced a fasting state. In this study, Takanori Yokota and his colleagues loaded PMs with fragments of anti-AβO antibodies, injected them into a mouse model of AD, and evaluated their effects on the brain and behavior.
“The results were very clear,” explains lead author Nobuo Sanjo. “PM-mediated administration of anti-AβO antibody fragments significantly reduced the amount of toxic Aβ in a variety of species. was smaller and less dense.
The researchers then analyzed the behavior of the mice and found that mice treated with antibody fragment-filled PMs had better learning and spatial memory than untreated mice. Our findings suggest that using PMs to deliver sufficient levels of antibodies to the brain could reduce the toxic A? slowing the progression of Alzheimer’s disease in mice,” Amano said. says.
Given the anti-A failure? Antibodies that improve cognition in human clinical trials are likely to be inadequately supplied in the brain, so PM-encapsulated antibody fragments could be an effective way to prevent the progression of AD. there is. Moreover, new candidates for AD therapy that degrade toxic Aβ and mitigate its toxic effects may also be delivered to the brain using the same PM-based system.
Original: Transporting antibodies across the blood-brain barrier to treat Alzheimer’s disease
Than: Tokyo Medical and Dental University
